Bioinformatic discovery platform that uses fold recognition algorithms to scan the AlphaFold database and identify novel pore-forming proteins in maize, soybean, Arabidopsis, and other crop plants. These proteins can be characterized, modified, and engineered to deliver targeted insecticidal and nematocidal activity for crop protection applications.
This solution leverages bioinformatic fold recognition algorithms to mine the AlphaFold structural database and uncover novel, previously uncharacterized pore-forming proteins in major crop species including maize, soybean, rice, and Arabidopsis. Pore-forming proteins are a proven mechanism for pest control in agriculture, and this approach enables the systematic discovery of new candidates that may serve as plant immunity proteins with native insecticidal or nematocidal activity. The platform supports both the identification of new pore-forming agents and the engineering of their specificity through mutagenesis and receptor-binding domain modifications, allowing activity to be redirected toward specific pests.
Discovery and identification:
Modification and engineering:
Validation pipeline:
The bioinformatic discovery pipeline is already operational, with dozens of novel pore-forming protein candidates identified in maize, soybean, and rice. The fold-mining method has been validated through prior success in identifying novel pore-forming proteins in humans. The team has demonstrated the ability to modify receptor binding domains to alter lipid specificity in related fungal proteins. The bioinformatics analysis phase requires approximately 4-8 weeks, while expression, purification, and screening of candidate molecules is estimated at 6-8 months. The next phase of work will focus on expanding the candidate list, curating the best candidates for biochemical and structural investigation, and engineering insect-specific variants of the most promising pore-forming proteins.
Monash University is a comprehensive public research university and one of Australia’s largest, known for scale, interdisciplinarity, and an applied orientation. Its Melbourne-based technology precinct brings together university laboratories, pilot-scale and prototyping suites, and company R&D groups alongside government research organizations to enable co-development and rapid iteration. Integration with a major hospital network supports clinical trials and translation, while structured industry placements and doctoral partnerships create a robust talent pipeline for corporate R&D. Research is backed by competitive funding from the Australian Research Council, the National Health and Medical Research Council, and state and federal programs that incentivize industry collaboration. A dedicated technology transfer office manages IP, licensing, and startup formation, with pathways to incubation and investment within the precinct.